Skip to content

Shattuck Labs, Inc. STTK Available-for-Sale Debt Securities - Amortized Cost

Available-for-Sale Debt Securities - Amortized Cost at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$586.4M-6.6%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$59.07M-71.3%
Zymeworks logo
ZymeworksZYME
$120.41M-36.3%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$695.19M+281%
Amgen logo
AmgenAMGN
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost?
Shattuck Labs, Inc. (STTK) reported available-for-sale debt securities - amortized cost of $88.86M in Q1 2026.
How has Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost changed year-over-year?
Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost increased by 48.6% year-over-year, from $59.79M to $88.86M.
What is the long-term trend for Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost?
Over 5 years (2020 to 2025), Shattuck Labs, Inc.'s available-for-sale debt securities - amortized cost has grown at a -15.6% compound annual growth rate (CAGR), from $177.61M to $76.14M.
What does available-for-sale debt securities - amortized cost mean?
This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.